Leerink Partnrs Analysts Reduce Earnings Estimates for ACAD

Key Points

• Leerink Partners has cut its FY2025 earnings per share estimate for ACADIA Pharmaceuticals from $0.55 to $0.50, while the consensus estimate stands at $0.70 per share.
• In its latest quarterly earnings announcement, ACADIA reported an EPS of $0.16, which exceeded expectations, and a revenue of $264.57 million, up 9.4% year-over-year.
• ACADIA Pharmaceuticals has garnered a consensus "Moderate Buy" rating from analysts, with a target price averaging around $28.53, though ratings vary from "sell" to "strong buy."

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn $0.50 per share for the year, down from their prior estimate of $0.55. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' Q4 2025 earnings at $0.08 EPS.

Several other research analysts have also recently commented on the stock. HC Wainwright restated a "buy" rating and set a $32.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. JPMorgan Chase & Co. increased their price objective on shares of ACADIA Pharmaceuticals from $30.00 to $34.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Wall Street Zen raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley set a $24.00 target price on ACADIA Pharmaceuticals and gave the stock an "equal weight" rating in a report on Tuesday, May 20th. Finally, UBS Group set a $36.00 price target on ACADIA Pharmaceuticals and gave the company a "buy" rating in a research note on Friday. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $28.88.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD traded up $0.20 during trading hours on Friday, reaching $24.60. 1,667,971 shares of the stock were exchanged, compared to its average volume of 1,695,475. The stock has a market cap of $4.12 billion, a PE ratio of 18.50, a PEG ratio of 7.00 and a beta of 0.70. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $25.23. The firm has a 50 day moving average of $22.38 and a 200 day moving average of $19.27.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%. The company had revenue of $264.57 million during the quarter, compared to analysts' expectations of $263.07 million. During the same period in the prior year, the firm earned $0.20 earnings per share. ACADIA Pharmaceuticals's revenue for the quarter was up 9.4% compared to the same quarter last year.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total transaction of $314,633.88. Following the completion of the sale, the director directly owned 15,095 shares in the company, valued at $328,769.10. This trade represents a 48.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 2,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the transaction, the executive vice president directly owned 62,130 shares in the company, valued at $1,553,250. The trade was a 3.12% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,446 shares of company stock worth $454,634. Insiders own 26.50% of the company's stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Exchange Traded Concepts LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $29,000. Banque Transatlantique SA acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth approximately $31,000. Picton Mahoney Asset Management acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth approximately $32,000. Federated Hermes Inc. increased its position in shares of ACADIA Pharmaceuticals by 231.5% in the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,618 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at about $39,000. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.